Keytruda Poised To Add Early TNBC To Its Resumé As KEYNOTE-522 Hits First Endpoint

Early data from the first Phase III trial of an immunotherapy - Merck & Co. Inc.’s Keytruda - in addition to chemotherapy in the neoadjuvant/adjuvant setting in early triple-negative breast cancer are looking promising, with a significant benefit seen on pathological complete response and a trend towards a benefit on event-free survival.

The data from the KEYNOTE-522 trial were presented at the European Society of Medical Oncology meeting in Barcelona, Spain, on 29 September, to cautious acclaim as the survival data still...